^
Association details:
| Biomarker: | NF1 mutation |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma
Published date:
07/07/2023
Excerpt:
The purpose of the current retrospective analysis was to evaluate whether the mutational signature of metastatic melanoma had an impact on ICI treatment outcomes such as progression-free and overall survival....The percentage of patients who achieved CR as the BORR after initial ICI treatment was 45.5% for the BRAF V600 mutation subset, 38.5% for NRAS mutant patients, 37.5% for NF1 mutant patients, and 55.6% for triple negative patients (p > 0.05 via chi-square test). No patients with a BRAF fusion or gene rearrangement responded to ICI or 2nd line PD-1 antibody plus targeted therapy treatment (BORR of 0%)....
DOI:
https://doi.org/10.3390/cancers15133527
Source:
Title:
1043P - NF1 mutations and immune checkpoint inhibitor outcomes in patients with BRAF wildtype melanoma
Published date:
09/13/2021
Excerpt:
Treatment responses were seen in 82.4% (14/17) NF1 mut pts and in 49% (25/51) NRAS/tWT pts treated with ICI (p=0.016)....Our data provide external validation to independent observations that NF1 mut are associated with improved ICI outcomes in pts with BRAF V600 WT metastatic cutaneous melanoma.
